Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk?

Aesthetic plastic surgery 2023 Vol.47(3) p. 914-926

Santanelli di Pompeo F, Sorotos M, Clemens MW, Paolini G, Anibaldi P, Davoli M, Baglio G, Pinnarelli L, Ferranti M, Cerza F, Cicala SD, Firmani G

관련 도메인

Abstract

[BACKGROUND] Because of poor knowledge of risks and benefits, prophylactic explantation of high BIA-ALCL risk breast implant (BI) is not indicated. Several surgical risks have been associated with BI surgery, with mortality being the most frightening. Primary aim of this study is to assess mortality rate in patients undergoing breast implant surgery for aesthetic or reconstructive indication.

[MATERIALS AND METHODS] In this retrospective observational cohort study, Breast Implant Surgery Mortality rate (BISM) was calculated as the perioperative mortality rate among 99,690 patients who underwent BI surgery for oncologic and non-oncologic indications. Mean age at first implant placement (A1P), implant lifespan (IL), and women's life expectancy (WLE) were obtained from a literature review and population database.

[RESULTS] BISM rate was 0, and mean A1P was 34 years for breast augmentation, and 50 years for breast reconstruction. Regardless of indication, overall mean A1P can be presumed to be 39 years, while mean BIL was estimated as 9 years and WLE as 85 years.

[CONCLUSION] This study first showed that the BISM risk is 0. This information, and the knowledge that BI patients will undergo one or more revisional procedures if not explantation during their lifetime, may help surgeons in the decision-making process of a pre-emptive substitution or explant in patients at high risk of BIA-ALCL. Our recommendation is that patients with existing macrotextured implants do have a relative indication for explantation and total capsulectomy. The final decision should be shared between patient and surgeon following an evaluation of benefits, surgical risks and comorbidities.

[LEVEL OF EVIDENCE IV] This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 breast 유방 dict 6
합병증 bia-alcl 보형물연관 역형성대세포림프종 dict 3
시술 breast augmentation 유방성형술 dict 1
합병증 breast implant scispacy 1
약물 A1P scispacy 1
약물 [BACKGROUND] scispacy 1
약물 [RESULTS] BISM scispacy 1
질환 breast implant C0178391
breast implant procedure
scispacy 1
질환 99,690 scispacy 1
질환 WLE → women's life expectancy scispacy 1
기타 patients scispacy 1
기타 A1P scispacy 1
기타 women scispacy 1
기타 BIL scispacy 1
기타 patient scispacy 1

MeSH Terms

Humans; Female; Breast Implants; Retrospective Studies; Treatment Outcome; Breast Implantation; Mammaplasty; Lymphoma, Large-Cell, Anaplastic; Breast Neoplasms; Observational Studies as Topic

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문